This was a moment years in the making for interventional cardiology. A total of 164 training programs participated, and 94% of applicants secured a position. 

The news comes at the end of a busy year for Cleerly. The company says it will use the funds to grow commercially and generate more evidence in support of its FDA-approved technology.

The technique was especially cost-effective in outpatient settings, according to a new study of more than 22,000 patients.

The heightened risks were even seen in women who were never diagnosed with a psychiatric disorder. It remains unclear why the same trend was not seen in men.

It's early for RAVR, but the minimally invasive technique has already started gaining momentum as an alternative to both SAVR and TAVR. We spoke to Vinay Badhwar, MD, one of the world’s leading voices in robotic heart surgery, to learn more.

“Most of us need to begin shifting our diets toward plant-based proteins,” according to one Harvard researcher. 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Medtronic designed its new Smart MDI system to provide real-time insights to users on multiple daily injection therapy.

A line of syringes manufactured by Cardinal Health may fail to properly inject insulin when used with needleless IV connectors. 

The system combines findings from SPECT myocardial perfusion imaging with lifestyle and clinical factors to predict risk of major cardiovascular events.